Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALT | Common Stock, par value $0.0001 | Options Exercise | $52K | +20K | +235.35% | $2.60 | 28.5K | Dec 22, 2022 | Direct | |
transaction | ALT | Common Stock, par value $0.0001 | Sale | -$300K | -20K | -70.18% | $15.01 | 8.5K | Dec 22, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALT | Stock Options (option to buy) | Options Exercise | $0 | -20K | -100% | $0.00* | 0 | Dec 22, 2022 | Common Stock, par value $0.0001 | 20K | $2.60 | Direct | F3 |
Id | Content |
---|---|
F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.0000 to $15.0900, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
F3 | The option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. |